Skip to content

Intravenous Infusion of Lidocaine in Gastroscopy

Efficacy of Intravenous Infusion of Lidocaine in Sedation for ERCP: a Randomised Placebo-controlled Study

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04439773
Enrollment
130
Registered
2020-06-19
Start date
2020-07-01
Completion date
2020-12-31
Last updated
2020-06-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sedation

Keywords

intravenous lidocaine gastroscopy bucking

Brief summary

Intravenous infusion of lidocaine significantly reduces incidence of bucking when perfomed gastroscopy.

Detailed description

This study divide patients into two groups, the patients in lidocaine group will be given lidocaine; the control group will be given placebo .the primary endopiont was to investigate whether intravenous lidocaine can reduce incidence of bucking and movement in sedation of gastroscopy.

Interventions

DRUGLidocaine

the experimental group will be given 1-1.5mg/kg lidocaine and then 2mg/kg/h

DRUGplacebo

the control group will be given the same volume of saline.

Sponsors

Shandong University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Intervention model description

Participants are randomly assigned to controll group or lidocaine group. Participants of control group are given placebo while participants of lidocaine group are given lidocaine.

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

patients aged \>18 years who were scheduled for ERCP at Qilu hospital.

Exclusion criteria

patients with ASA (American Society of Anesthesiologists) Class 4 or 5, pre-existing hypoxemia (SpO2 \<90%), hypotension (systolic blood pressure \<90 mm Hg), bradycardia (HR\<50 beats/min), uncontrolled hypertension (SBP \>170 mm Hg, diastolic blood pressure\>100 mm Hg), severe renal or liver failure, pregnancy or lactation, allergy to lidocaine, atrioventricular block, epilepsy, and inability to give informed consen

Design outcomes

Primary

MeasureTime frameDescription
the incidence of bucking during the procedurehalf a yearthe difference between incidence of bucking of the two groups

Secondary

MeasureTime frameDescription
the incidence of infusion pain when adminstrated propofolhalf a yearthe infusion pain devied into no pain, mild pian, and severe pain
Safety assessed by the rate of hypoxia during the procedurehalf a yearHypoxia, defined as peripheral oxygen saturation \<90% for \>30 seconds
Safety assessed by the rate of hypotention during the procedurehalf a yearHypotension, defined as systolic blood pressure \<90 mmHg
Safety assessed by the rate of breadycardia during the procedurehalf a yearBradycardia, defined as heart rate \<50 beats/min
Safety assessed by the rate of required airway management during the procedurehalf a yearRequired airway management such as jaw lifting, mask ventilation, or tracheal intubation in severe hypoxia Required airway management such as jaw lifting, mask ventilation, or tracheal intubation in severe hypoxia
propofol consumption difference between the two groupshalf a yearthe total propofol dosage consumption between the two groups
patient satisfaction assessed by the patienthalf a yearthe patient satisfacition score were assessed on a 0-10VAS 30mins after the procedure
anesthetist satisfactionhalf a yearthe anesthetist satisfacition score were assessed on a 0-10VAS 30mins after the procedure
pain socre after the gastroscopyhalf a yearpain were measured on a 0-10VAS at arrival in the recovery room ,30min later
fatigue score after the ERCPhalf a yearfatigue were measured on a 0-10VAS at arrival in the recovery room ,30min later
endoscopists satisfaction assessed by the performerhalf a yearthe endoscopists satisfacition score were assessed on a 0-10VAS after the procedure

Countries

China

Contacts

Primary Contactjing Liu
liujingqilu@126.com+86-18560083755
Backup Contactyanqing li
liyanqing@sdu.edu.cn86-531-82169236

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026